We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Docetaxel Appears to Be Effective in Liver Metastases

Apr 1, 1995
Volume: 
4
Issue: 
4
  • Breast Cancer, Palliative and Supportive Care

SAN ANTONIO--Use of docetaxel (Taxotere) as palliative treatment
of advanced breast cancer produced durable responses in almost
70% of patients, including three fourths of those with liver metastases,
French researchers said at a poster session of the San Antonio
Breast Cancer Symposium.

In another poster presentation, investigators from San Antonio
reported a 57% response rate in patients with advanced breast
cancer that had proven resistant to treatment with doxorubicin
or mitoxantrone (Novantrone).

Bernard Chevallier, MD, described a study in which a 100 mg/m²
docetaxel dose every 3 weeks led to significant responses in 21
(68%) of 31 advanced breast cancer patients, including 12 of 16
with liver metastases. The response rate for liver metastases
is the highest yet reported for such an application of monotherapy,
said Dr. Chevallier, medical oncologist, Centre Henri Becquerel,
Rouen, France.

Breast cancer patients with liver metastases generally have a
poor prognosis with currently available chemotherapeutic regimens,
Dr. Chevallier noted. In preliminary clinical evaluations, docetaxel
has shown antitumor activity against liver and lung metastases
in heavily pretreated breast cancer patients, he said.

Of the 31 patients in the study, 11 had previously received chemotherapy,
and 10 of the 11 had been treated with an anthracycline. Patients
received a median of five cycles of docetaxel therapy. The median
cumulative dose was 489 mg, and median dose intensity was 97%.

Median Survival of 23 Months

Overall, 16 patients had partial responses, and five had complete
responses. Among previously treated patients, five of 11 had partial
responses, and two had complete responses. The median duration
of response was 44 weeks, and median survival was 23 months.

Pages

  • 1
  • 2
  • next ›
  • last »

Related Articles

  • Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
  • Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.